JointHealth™ express March 31, 2023
Ontario is following seven other Canadian provinces and territories in expanding the use of safe and effective biosimilar medication treatments for Ontarians. This special edition of JointHealth™ insight will cover the following:
Ontario is following seven other Canadian provinces and territories in expanding the use of safe and effective biosimilar medication treatments for Ontarians. This special edition of JointHealth™ insight will cover the following:
- New Ontario biosimilar transition policy
- What is a biosimilar biologic
- How the transition works for inflammatory arthritis patients
- Why public drug plans are transitioning patients from an originator biologic to a biosimilar biologic
- How to ensure a smooth transition from an originator biologic to a biosimilar biologic
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.